Stock Market News
Astra and MSD get positive cancer news from EU agency
AstraZeneca and US partner Merck & Co (MSD) have received a positive opinion from European drug regulators over their ovarian, fallopian tube, or peritoneal cancer therapy.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency indicated they were likely to recommend marketing approval for AstraZeneca and MSD's olaparib tablets, branded as Lynparza, as a twice daily maintenance therapy for patients who are in complete response or partial response to platinum-based chemotherapy.
Lynparza is recommended for treatment in this setting regardless of patients' BRCA mutation status.
Sean Bohen, Astra's chief medical officer, said: "The data show that Lynparza provides long-term disease control, delaying the need for further chemotherapy for this broader group of women with platinum-sensitive relapsed ovarian cancer, irrespective of their BRCA status. It also offers a well-characterised safety and tolerability profile, which is critical to help enable patients to stay on treatment."
The CHMP recommendation was based on two randomised trials, SOLO-2 and Study 19, which showed Lynparza reduced the risk of disease progression or death for platinum-sensitive relapsed patients compared to placebo.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency indicated they were likely to recommend marketing approval for AstraZeneca and MSD's olaparib tablets, branded as Lynparza, as a twice daily maintenance therapy for patients who are in complete response or partial response to platinum-based chemotherapy.
Lynparza is recommended for treatment in this setting regardless of patients' BRCA mutation status.
Sean Bohen, Astra's chief medical officer, said: "The data show that Lynparza provides long-term disease control, delaying the need for further chemotherapy for this broader group of women with platinum-sensitive relapsed ovarian cancer, irrespective of their BRCA status. It also offers a well-characterised safety and tolerability profile, which is critical to help enable patients to stay on treatment."
The CHMP recommendation was based on two randomised trials, SOLO-2 and Study 19, which showed Lynparza reduced the risk of disease progression or death for platinum-sensitive relapsed patients compared to placebo.
Related share prices |
---|
AstraZeneca (AZN) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price